• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在双打击/三打击时代诊断成熟侵袭性 B 细胞淋巴瘤的实用算法方法:选择病例,匹配临床获益:意大利血液病理学小组(G.I.E.)的立场文件。

A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit : A position paper from the Italian Group of Haematopathology (G.I.E.).

机构信息

Pathology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University, Via di Grottarossa 1035, 00189, Rome, Italy.

Pathology Unit, San Camillo-Forlanini Hospital, Rome, Italy.

出版信息

Virchows Arch. 2019 Oct;475(4):513-518. doi: 10.1007/s00428-019-02637-2. Epub 2019 Aug 6.

DOI:10.1007/s00428-019-02637-2
PMID:31388760
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6828632/
Abstract

An accurate diagnosis of clinically distinct subgroups of aggressive mature B cell lymphomas is crucial for the choice of proper treatment. Presently, precise recognition of these disorders relies on the combination of morphological, immunophenotypical, and cytogenetic/molecular features. The diagnostic workup in such situations implies the application of costly and time-consuming analyses, which are not always required, since an intensified treatment option is reasonably reserved to fit patients. The Italian Group of Haematopathology proposes herein a practical algorithm for the diagnosis of aggressive mature B cell lymphomas based on a stepwise approach, aimed to select cases deserving molecular analysis, in order to optimize time and resources still assuring the optimal management for any patient.

摘要

准确诊断临床上具有明显差异的侵袭性成熟 B 细胞淋巴瘤亚群对于选择适当的治疗方法至关重要。目前,这些疾病的精确识别依赖于形态学、免疫表型和细胞遗传学/分子特征的结合。在这种情况下,诊断工作需要进行昂贵且耗时的分析,但并非总是必要的,因为强化治疗方案通常仅适用于符合条件的患者。意大利血液病理学小组在此提出了一种基于逐步方法的侵袭性成熟 B 细胞淋巴瘤诊断的实用算法,旨在选择需要分子分析的病例,以优化时间和资源,同时确保为任何患者提供最佳治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c00/6828632/c840292d8d4d/428_2019_2637_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c00/6828632/968878f32b8a/428_2019_2637_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c00/6828632/268359e7458e/428_2019_2637_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c00/6828632/c840292d8d4d/428_2019_2637_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c00/6828632/968878f32b8a/428_2019_2637_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c00/6828632/268359e7458e/428_2019_2637_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c00/6828632/c840292d8d4d/428_2019_2637_Fig3_HTML.jpg

相似文献

1
A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit : A position paper from the Italian Group of Haematopathology (G.I.E.).在双打击/三打击时代诊断成熟侵袭性 B 细胞淋巴瘤的实用算法方法:选择病例,匹配临床获益:意大利血液病理学小组(G.I.E.)的立场文件。
Virchows Arch. 2019 Oct;475(4):513-518. doi: 10.1007/s00428-019-02637-2. Epub 2019 Aug 6.
2
Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.具有 BCL6 和 MYC 易位的双打击 B 细胞淋巴瘤是侵袭性的,常为结外淋巴瘤,与 BCL2 双打击 B 细胞淋巴瘤不同。
Am J Surg Pathol. 2013 Mar;37(3):323-32. doi: 10.1097/PAS.0b013e31826cebad.
3
Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.由于 t(3;8)(q27;q24)导致的具有假性双打击 BCL6-MYC 易位的淋巴瘤与生发中心免疫表型、结外累及和频繁的 BCL2 易位有关。
Hum Pathol. 2018 Oct;80:192-200. doi: 10.1016/j.humpath.2018.06.006. Epub 2018 Jun 11.
4
Morphological, immunophenotypic and molecular characterization of mature aggressive B-cell lymphomas in Chinese pediatric patients.中国儿科患者成熟侵袭性 B 细胞淋巴瘤的形态学、免疫表型和分子特征。
Leuk Lymphoma. 2011 Dec;52(12):2356-64. doi: 10.3109/10428194.2011.602772. Epub 2011 Aug 18.
5
Advances in pathological understanding of high-grade B cell lymphomas.高级别B细胞淋巴瘤病理认识的进展
Expert Rev Hematol. 2018 Aug;11(8):637-648. doi: 10.1080/17474086.2018.1494567. Epub 2018 Jul 10.
6
Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.“双打击”弥漫性大B细胞淋巴瘤及具有弥漫性大B细胞淋巴瘤和伯基特淋巴瘤之间特征的不可分类B细胞淋巴瘤的诊断:时机与方法,荧光原位杂交(FISH)与免疫组化(IHC)对比
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):90-9. doi: 10.1182/asheducation-2014.1.90. Epub 2014 Nov 18.
7
Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.伴有MYC与BCL2、BCL6或CCND1重排的双打击B细胞淋巴瘤的临床病理特征
Pathol Int. 2015 Oct;65(10):519-27. doi: 10.1111/pin.12335. Epub 2015 Jul 29.
8
[Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases].[间期荧光原位杂交技术在B细胞淋巴瘤中的诊断及治疗价值:604例临床病理分析]
Zhonghua Bing Li Xue Za Zhi. 2018 Dec 8;47(12):920-925. doi: 10.3760/cma.j.issn.0529-5807.2018.12.005.
9
Evaluation of interphase fluorescence in situ hybridization for the t(14;18)(q32;q21) translocation in the diagnosis of follicular lymphoma on fine-needle aspirates: a comparison with flow cytometry immunophenotyping.细针穿刺抽吸物中用于诊断滤泡性淋巴瘤的t(14;18)(q32;q21)易位的间期荧光原位杂交评估:与流式细胞术免疫表型分析的比较
Cancer. 2003 Dec 25;99(6):385-93. doi: 10.1002/cncr.11787.
10
High-grade B-cell lymphoma: how to diagnose and treat.高级别 B 细胞淋巴瘤:如何诊断和治疗。
Expert Rev Hematol. 2019 Jul;12(7):497-506. doi: 10.1080/17474086.2019.1624157. Epub 2019 Jun 19.

引用本文的文献

1
A Diagnostic Approach in Large B-Cell Lymphomas According to the Fifth World Health Organization and International Consensus Classifications and a Practical Algorithm in Routine Practice.根据世界卫生组织第五版和国际共识分类对大B细胞淋巴瘤的诊断方法及常规实践中的实用算法
Int J Mol Sci. 2024 Dec 9;25(23):13213. doi: 10.3390/ijms252313213.
2
Combined immunohistochemical profile CD10/LMO2/MYC is a useful tool to screen MYC rearrangements in aggressive large B-cell lymphomas.联合免疫组化谱CD10/LMO2/MYC是筛查侵袭性大B细胞淋巴瘤中MYC重排的有用工具。
Virchows Arch. 2025 May;486(5):951-959. doi: 10.1007/s00428-024-03945-y. Epub 2024 Oct 22.
3

本文引用的文献

1
Using Gene Expression Profiling to Move Beyond MYC/BCL2 Rearrangements in High-Grade Lymphoma.利用基因表达谱超越高级别淋巴瘤中的MYC/BCL2重排
J Clin Oncol. 2019 Jan 20;37(3):175-177. doi: 10.1200/JCO.18.01910. Epub 2018 Dec 3.
2
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.MYC蛋白表达评分及其对侵袭性B细胞淋巴瘤患者预后的影响。
Haematologica. 2019 Jan;104(1):e25-e28. doi: 10.3324/haematol.2018.195958. Epub 2018 Jun 28.
3
Inferior survival in high-grade B-cell lymphoma with and and/or rearrangements is not associated with gene rearrangements.
Deep Learning for the Classification of Non-Hodgkin Lymphoma on Histopathological Images.
基于组织病理学图像的非霍奇金淋巴瘤深度学习分类
Cancers (Basel). 2021 May 17;13(10):2419. doi: 10.3390/cancers13102419.
4
High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.多重荧光原位杂交技术在同时检测 BCL2 和 BCL6 重排中的高灵敏度:在弥漫性大 B 细胞淋巴瘤的特征化中的有用应用。
Virchows Arch. 2021 Sep;479(3):565-573. doi: 10.1007/s00428-021-03084-8. Epub 2021 Mar 25.
5
Comparison of Ki-67 Labeling Index Patterns of Diffuse Large B-Cell Lymphomas and Burkitt Lymphomas Using Image Analysis: A Multicenter Study.利用图像分析比较弥漫性大B细胞淋巴瘤和伯基特淋巴瘤的Ki-67标记指数模式:一项多中心研究
Diagnostics (Basel). 2021 Feb 19;11(2):343. doi: 10.3390/diagnostics11020343.
6
Gastrointestinal lymphoproliferative lesions: a practical diagnostic approach.胃肠道淋巴组织增生性病变:一种实用的诊断方法。
Pathologica. 2020 Sep;112(3):227-247. doi: 10.32074/1591-951X-161.
7
Double Hit Lymphoma Diagnosis and Treatment in Europe-A Cross-Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG).欧洲双打击淋巴瘤的诊断与治疗——欧洲血液学协会淋巴瘤工作组(EHA LyG)的临床实践横断面调查
Hemasphere. 2020 Oct 20;4(6):e481. doi: 10.1097/HS9.0000000000000481. eCollection 2020 Dec.
8
Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.弥漫性大 B 细胞淋巴瘤的肿瘤内异质性涉及诱导多样化的基质-肿瘤界面。
EBioMedicine. 2020 Nov;61:103055. doi: 10.1016/j.ebiom.2020.103055. Epub 2020 Oct 20.
伴有 和/或 重排的高级别 B 细胞淋巴瘤患者的生存情况较差,但与 基因重排无关。
Haematologica. 2018 Nov;103(11):1899-1907. doi: 10.3324/haematol.2018.190157. Epub 2018 Jun 14.
4
High-grade B-cell lymphoma with and and/or rearrangements with diffuse large B-cell lymphoma morphology.伴有 和/或 重排的高级别 B 细胞淋巴瘤,伴弥漫性大 B 细胞淋巴瘤形态学特征。
Blood. 2018 May 3;131(18):2060-2064. doi: 10.1182/blood-2017-12-820605. Epub 2018 Feb 23.
5
Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.伴有 MYC 和 BCL2 及/或 BCL6 重排的高级别 B 细胞淋巴瘤的诊断与治疗方法。
Blood. 2017 Jan 19;129(3):280-288. doi: 10.1182/blood-2016-02-636316. Epub 2016 Nov 7.
6
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.MYC-IG 重排是接受免疫化疗治疗的弥漫性大 B 细胞淋巴瘤患者生存的负预测因子:GELA/LYSA 研究。
Blood. 2015 Nov 26;126(22):2466-74. doi: 10.1182/blood-2015-05-647602. Epub 2015 Sep 15.
7
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.西方国家原发性CD5+弥漫性大B细胞淋巴瘤的临床和生物学意义。
Oncotarget. 2015 Mar 20;6(8):5615-33. doi: 10.18632/oncotarget.3479.
8
MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection.MYC 状态测定在侵袭性 B 细胞淋巴瘤中的作用:FISH 探针选择的影响。
Histopathology. 2013 Sep;63(3):418-24. doi: 10.1111/his.12178. Epub 2013 Jun 24.
9
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗弥漫性大 B 细胞淋巴瘤时 MYC 和 BCL2 的共表达。
J Clin Oncol. 2012 Oct 1;30(28):3452-9. doi: 10.1200/JCO.2011.41.0985. Epub 2012 Jul 30.
10
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.免疫组化双打击评分是利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗弥漫性大 B 细胞淋巴瘤患者预后的强有力预测指标。
J Clin Oncol. 2012 Oct 1;30(28):3460-7. doi: 10.1200/JCO.2011.41.4342. Epub 2012 Jun 4.